Baxter International (BAX)

Every day, millions of patients and caregivers rely on Baxter's leading portfolio of critical care, nutrition, renal, hospital and surgical products. For more than 85 years, it has been operating at the critical intersection where innovations that save and sustain lives meet the healthcare providers that make it happen. With products, technologies and therapies available in more than 100 countries, Baxter's employees worldwide are now building upon the company's rich heritage of medical breakthroughs to advance the next generation of transformative healthcare innovations.

Company profile

Ticker

BAX

Exchange

NYSE

Website

www.baxter.com

CEO

Jose Almeida

Incorporated

Delaware

Location

Illinois

Fiscal year end

Dec 31

Sector

Manufacturing > Surgical and Medical Instrument Manufacturing

Industry (SIC)

Surgical & Medical Instruments & Apparatus

3M • Boston Scientific • Stryker • Becton, Dickinson And • Teleflex • Resmed • Hill-Rom • Nuvasive • Integra Lifesciences • Embecta ...

SEC CIK

0000010456

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Indentures

Material Contracts & Credit Agreements

Subsidiaries Lists

Subsidiaries

Baxter Corporation • Baxter Healthcare Corporation • Baxter Pharmaceutical Solutions LLC • Baxter Sales and Distribution LLC • Cheetah Medical, Inc. • Gambro Renal Products, Inc. • Gambro UF Solutions, Inc. • Hill-Rom Holdings, Inc • Laboratorios Baxter S.A. • Synovis Life Technologies, Inc. ...

IRS number

360781620

BAX stock data

1M 1Y 5Y

News

From Benzinga Pro

Where Baxter Intl Stands With Analysts

17 May 22

Within the last quarter, Baxter Intl (NYSE:BAX) has observed the following analyst ratings:

Citigroup Maintains Buy on Baxter Intl, Lowers Price Target to $85

17 May 22

Citigroup analyst Joanne Wuensch maintains Baxter Intl (NYSE:BAX) with a Buy and lowers the price target from $98 to $85.

Baxter International's Return on Invested Capital Overview

3 May 22

Pulled from Benzinga Pro data, Baxter International (NYSE:BAX) showed a loss in earnings since Q4, totaling $73.00 million. Sales, on the other hand, increased by 5.49% to $3.71 billion during Q1.

Stocks That Hit 52-Week Lows On Friday

29 Apr 22

Analyst Ratings for Baxter Intl

29 Apr 22

Press releases

From Benzinga Pro

Baxter to Host 2022 Investor Conference

10 May 22

Baxter International Inc. (NYSE:BAX), a global medtech leader, will host an investor conference on Wednesday, May 25, 2022 in Glenview, Ill. Chairman and CEO Joe Almeida and other members of Baxter's management team

Baxter Increases Dividend and Declares Quarterly Dividend

3 May 22

Baxter International Inc. (NYSE:BAX), a leading global medtech company, today announced an increase in the company's quarterly cash dividend to a rate of $0.29 per share of common stock. This represents an approximately

BAXTER HIGHLIGHTS NEW DATA AT SCCM CRITICAL CARE CONGRESS SHOWING HEMODYNAMIC MONITORING MAY HELP PREDICT PATIENT OUTCOMES

19 Apr 22

Findings suggest that monitoring changes in stroke volume and cardiac output could help predict mortality in critically ill patientsBaxter-sponsored symposium advances expert dialogue on fluid managementDEERFIELD, Ill.,

Baxter Highlights New Data at SCCM Critical Care Congress Showing Hemodynamic Monitoring May Help Predict Patient Outcomes

19 Apr 22

Medical Adhesive Market Analysis, Market Size, Competitive Strategies, Forecasts to 2028

30 Mar 22

Analyst ratings and price targets

Last 3 months

Average target

$87.80

Low target

$77.00

High target

$100.00

Calendar

28 Apr 22

17 May 22

31 Dec 22

Financial summary

Financial statements Chart BAX financial data

Quarter (USD)	Mar 22	Dec 21	Sep 21	Jun 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 21	Dec 20	Dec 19	Dec 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	2.3B	2.3B	2.3B	2.3B	2.3B	2.3B
Cash burn (monthly)	219M	73.92M	(no burn)	(no burn)	(no burn)	(no burn)
Cash used (since last report)	340.02M	114.76M	n/a	n/a	n/a	n/a
Cash remaining	1.96B	2.18B	n/a	n/a	n/a	n/a
Runway (months of cash)	8.9	29.5	n/a	n/a	n/a	n/a

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Recent insider trades

BAX insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	#Shares	#Remaining
10 May 22	David Brent Shafer	Common Stock, $1 par value	Grant	Acquire A	No	No	2,481	2,481
10 May 22	Peter M Wilver	Common Stock, $1 par value	Grant	Acquire A	No	No	2,481	2,481
3 May 22	Chen Thomas F	Common Stock, $1 par value	Grant	Acquire A	No	No	2,706	15,740

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

Institutional ownership, Q4 2021

BAX institutional ownership history Ownership history

84.9% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	1121	1060	+5.8%
Opened positions	152	80	+90.0%
Closed positions	91	98	-7.1%
Increased positions	347	356	-2.5%
Reduced positions	385	382	+0.8%

13F shares	Current	Prev Q	Change
Total value	36.71B	33.87B	+8.4%
Total shares	427.62M	420.89M	+1.6%
Total puts	2.06M	1.85M	+11.7%
Total calls	1.36M	2.2M	-38.2%
Total put/call ratio	1.5	0.8	+80.8%

Largest owners	Shares	Value	Change
Wellington Management	49.65M	$4.26B	-1.8%
BLK Blackrock	40.11M	$3.44B	+2.6%
Vanguard	38.98M	$3.35B	+0.1%
MS Morgan Stanley	28.38M	$2.44B	+1.8%
STT State Street	21.61M	$1.86B	+3.2%
Generation Investment Management	21.17M	$1.82B	+2.1%
Veritas Asset Management	12.22M	$1.05B	+9.9%
Geode Capital Management	8.72M	$746.52M	+6.6%
AMP Ameriprise Financial	7.1M	$609.24M	+15.1%
State Farm Mutual Automobile Insurance	6.85M	$588.3M	0.0%

Largest transactions	Shares	Bought/sold	Change
Norges Bank	5.55M	+5.55M	NEW
MCQEF Macquarie	6.68M	+4.65M	+229.8%
Caisse De Depot Et Placement Du Quebec	4.83M	-2.19M	-31.2%
Lazard Asset Management	26.76K	-2.12M	-98.8%
Capital World Investors	1.53M	-1.1M	-41.8%
Veritas Asset Management	12.22M	+1.1M	+9.9%
Millennium Management	3.72M	+1.06M	+40.1%
BLK Blackrock	40.11M	+1.03M	+2.6%
BMO Bank of Montreal	1.46M	-1.02M	-41.1%
JPM JPMorgan Chase & Co.	1.42M	+935.66K	+194.2%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Financial report summary

Competition

Axogen • ThermoGenesis • AIM ImmunoTech • Sangamo Therapeutics • United Health Products • Edwards Lifesciences • Curis • Lemaitre Vascular • Nephros • GlycoMimetics

Management Discussion

Net income attributable to Baxter stockholders for the three months ended March 31, 2022 totaled $71 million, or $0.14 per diluted share, compared to $298 million, or $0.58 per diluted share, for the three months ended March 31, 2021. The first quarter of 2022 is the first full quarter reflecting Hillrom results of operations after the December 13, 2021 acquisition. Net income for the three months ended March 31, 2022 included special items which decreased net income by $400 million, or $0.79 per diluted share, respectively, as further discussed below. Net income for the three months ended March 31, 2021 included special items which decreased net income by $88 million, or $0.18 per diluted share, as further discussed below.

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: acknowledged, added, admitting, answer, assembled, Back, bariatric, birthing, Build, Canada, cardiology, climate, collection, competitor, compliant, confidence, conflict, constitute, conversion, denying, desire, desist, diagnose, entity, escalation, exceeded, extinguishment, female, field, fiscal, framework, freight, front, frozen, functional, geopolitical, ill, inflation, Inspector, installation, lack, legacy, Linet, Lira, macroeconomic, maternal, nonpublic, nosocomial, Omicron, outbound, parent, peak, pelvic, penalty, Pfizer, physical, pneumonia, political, preceding, precision, preferred, quantify, repaid, review, Russia, screening, sentence, serving, Sherman, situation, skin, specialty, subpoena, therapy, thousand, Turkey, Turkish, Ukraine, variety, video, vision, war, warranty, workforce, Zosyn

Removed: allocating, appeal, applying, approach, assessing, aware, Baxalta, branded, cancer, chemotherapy, closed, combination, Concurrent, conspiracy, cooperate, covering, disaggregation, Division, doxorubicin, Eastern, exercise, existed, expire, extended, finalize, forma, geographical, German, GlaxoSmithKline, grand, improvement, institutional, Irvine, issuance, Johnson, jury, Justice, license, liposomal, managed, manufacturer, matter, medicine, met, moved, nausea, notified, occurred, output, parallel, Pennsylvania, permitted, positive, postponed, prejudice, pro, reallocate, reallocated, reallocation, recast, reduction, referred, region, relationship, relied, requested, restrict, restructure, saline, seeking, Shire, shortage, single, Specifically, TDS, testimony, upfront, voluntary, vomiting, weakening, York

From filing 10-Q 2022 Q1

Financial reports

View all